Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: November 2013 HVC Advocate Newletter


Guru

Status: Offline
Posts: 895
Date:
RE: November 2013 HVC Advocate Newletter
Permalink  
 


Interesting study, I have to say I would take off label in a shot for the cross company collaboration:

Gilead (Sofosbuvir) and BMS (Daclatasvir)
A small Phase 2 study of HCV genotype 1 (126 patients) and genotype 2 or 3 (44 patients) were treated for 12 or 24 weeks with the combination of 2 HCV polymerase inhibitors (daclatasvir and sofosbuvir) with and without ribavirin.  The genotype 1 patients achieved cure rates of 96 to 98%, while genotype 2 and 3 patients achieved cure rates of 93%



__________________

Genotype: 3b

VL.�over 15, 000 000

Failed TX 2014: Interferon/Riba.

Cured using Sof/Dak combination.

I can eat cake again! <3 



Guru

Status: Offline
Posts: 5627
Date:
Permalink  
 

This months newsletter from the HCV Advocate website includes interesting articles on military veterans and exposure to Hep C, and the`off-label` use of prescription drugs. 

http://www.hcvadvocate.org/news/newsLetter/2013/advocate1113.html#4



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.